Asthma/COPD:

Indications for SPIRIVA RESPIMAT:

Long-term maintenance treatment of bronchospasm due to COPD, including chronic bronchitis and emphysema. To reduce exacerbations of COPD. Long-term maintenance treatment of asthma in patients ≥6yrs of age.

Adult:

COPD: 2 inh of Spiriva Respimat 2.5mcg/actuation (5mcg) once daily. Asthma: 2 inh of Spiriva Respimat 1.25mcg/actuation (2.5mcg) once daily; may take up to 4–8 weeks for max benefits. Max: 2 inh/24hrs.

Children:

Asthma: <6yrs: not established. ≥6yrs: 2 inh of Spiriva Respimat 1.25mcg/actuation (2.5mcg) once daily; may take up to 4–8 weeks for max benefits. Max: 2 inh/24hrs.

Contraindications:

Allergy to ipratropium.

Warnings/Precautions:

Not for the relief of acute symptoms. Discontinue if immediate hypersensitivity reactions (eg, angioedema) or paradoxical bronchospasm occurs; consider alternative therapy. Monitor for signs/symptoms of worsening narrow-angle glaucoma or worsening urinary retention (esp. GI or GU obstruction). Moderate-to-severe renal impairment; monitor for anticholinergic effects. Allergy to atropine or its derivatives; monitor. HandiHaler: avoid getting powder into eyes; or allergy to milk proteins. Pregnancy. Nursing mothers.

See Also:

Pharmacologic Class:

Long-acting anticholinergic.

Interactions:

Avoid other anticholinergics.

Adverse Reactions:

Upper respiratory tract infection, dry mouth, sinusitis, pharyngitis, bronchitis, cough, headache, non-specific chest pain, UTI, dyspepsia, rhinitis, other anticholinergic effects (eg, urinary retention, constipation, dysuria, tachycardia, blurred vision, glaucoma); paradoxical bronchospasm.

Generic Availability:

NO

How Supplied:

HandiHaler (caps w. inh device)—5, 30, 90; Respimat (cartridge w. inh device)—4g (60 inh)